S&P 500
(0.07%) 5 252.10 points
Dow J
(-0.06%) 39 735 points
Nasdaq
(0.01%) 16 401 points
Oil
(1.34%) $82.44
Gas
(0.52%) $1.727
Gold
(1.79%) $2 229.80
Silver
(0.46%) $24.87
Platinum
(1.36%) $922.10
USD/EUR
(0.25%) $0.926
USD/NOK
(0.57%) $10.83
USD/GBP
(0.01%) $0.791
USD/RUB
(-0.32%) $92.15

Realtime updates for Ionis Pharmaceuticals Inc [IONS]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
62.50%
return -2.04%
SELL
34.38%
return 7.05%
Last Updated28 Mar 2024 @ 10:47

-0.58% $ 44.40

SELL 1406 min ago

@ $44.72

Issued: 27 Mar 2024 @ 11:21


Return: -0.70%


Previous signal: Mar 26 - 15:44


Previous signal: Buy


Return: 0.48 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 10:47):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy...

Stats
Today's Volume 81 825.00
Average Volume 1.20M
Market Cap 6.47B
EPS $0 ( 2024-02-21 )
Next earnings date ( $-1.110 ) 2024-05-01
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -17.34
ATR14 $0.548 (1.23%)
Insider Trading
Date Person Action Amount type
2024-02-26 Jenne Kyle Buy 65 203 Non-Qualified Stock Option (right to buy)
2024-02-26 Jenne Kyle Sell 0 Common Stock
2024-02-29 Swayze Eric Buy 605 Common Stock
2024-02-29 Monia Brett P Buy 538 Common Stock
2024-02-29 Geary Richard S Buy 604 Common Stock
INSIDER POWER
55.80
Last 100 transactions
Buy: 1 323 866 | Sell: 373 653

Volume Correlation

Long: 0.67 (moderate)
Short: 0.61 (weak)
Signal:(50) Neutral

Ionis Pharmaceuticals Inc Correlation

10 Most Positive Correlations
ALVR0.928
BGFV0.913
GRNA0.902
INFI0.897
CARE0.895
CMCT0.893
GBCI0.889
EQ0.889
BIOC0.885
CRBU0.882
10 Most Negative Correlations
STAY-0.908
TRMD-0.878
BCOR-0.875
PAYA-0.873
IBEX-0.868
PDFS-0.867
BNIXU-0.866
TGLS-0.865
LRFC-0.865
ARDX-0.861

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ionis Pharmaceuticals Inc Correlation - Currency/Commodity

The country flag -0.21
( neutral )
The country flag -0.07
( neutral )
The country flag 0.00
( neutral )
The country flag -0.60
( weak negative )
The country flag 0.66
( moderate )
The country flag 0.67
( moderate )

Ionis Pharmaceuticals Inc Financials

Annual 2023
Revenue: $787.65M
Gross Profit: $778.51M (98.84 %)
EPS: $-2.56
Q4 2023
Revenue: $324.51M
Gross Profit: $321.44M (99.06 %)
EPS: $-0.0643
Q3 2023
Revenue: $144.00M
Gross Profit: $142.00M (98.61 %)
EPS: $-1.030
Q2 2023
Revenue: $188.00M
Gross Profit: $185.00M (98.40 %)
EPS: $-0.600

Financial Reports:

No articles found.

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators